Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. PuriBlood Medical Co's Revenue for the
six
months ended in Dec. 2025 was NT$42.09 Mil. PuriBlood Medical Co's average Accounts Receivable for the
six
months ended in Dec. 2025 was NT$16.67 Mil.
Hence, PuriBlood Medical Co's Receivables Turnover for the
six
months ended in Dec. 2025 was 2.52.
PuriBlood Medical Co (ROCO:6847) Receivables Turnover Explanation
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
PuriBlood Medical Co Receivables Turnover Related Terms
PuriBlood Medical Co Receivables Turnover Historical Data
* Premium members only.
The historical data trend for PuriBlood Medical Co's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6847 vs TMO, DHR, IDXX: Receivables Turnover Comparison
For the Diagnostics & Research subindustry, PuriBlood Medical Co's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PuriBlood Medical Co Receivables Turnover vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, PuriBlood Medical Co's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where PuriBlood Medical Co's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PuriBlood Medical Co (ROCO:6847) has a Receivables Turnover of 2.52 as of Dec. 2025. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on PuriBlood Medical Co and its competitors. According to the industry distribution chart, PuriBlood Medical Co ranks #112 out of 202 companies in the Medical Diagnostics & Research industry, placing it in the top 55.4%.
Is PuriBlood Medical Co's Receivables Turnover too high?
PuriBlood Medical Co's current Receivables Turnover is 2.52. The Medical Diagnostics & Research industry median Receivables Turnover is 5.39. PuriBlood Medical Co's value of 2.52 is 53.2% below this industry median. Based on the distribution chart, PuriBlood Medical Co ranks #112 out of 202 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, PuriBlood Medical Co has a GF Score™ of 72/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does PuriBlood Medical Co's Receivables Turnover compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, PuriBlood Medical Co ranks #112 out of 202 companies for Receivables Turnover. This places PuriBlood Medical Co in the lower half of its industry. The industry median Receivables Turnover is 5.39. PuriBlood Medical Co's value of 2.52 is 53.2% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Medical Diagnostics & Research company?
The median Receivables Turnover among Medical Diagnostics & Research companies is 5.39, based on 202 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PuriBlood Medical Co's current Receivables Turnover of 2.52 is 53.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on PuriBlood Medical Co and its competitors. For the Medical Diagnostics & Research industry, the median Receivables Turnover is 5.39 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PuriBlood Medical Co's current Receivables Turnover is 2.52. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PuriBlood Medical Co stock overvalued right now?
Based on GuruFocus' analysis, PuriBlood Medical Co (ROCO:6847) is currently considered Modestly Overvalued. The stock's GF Value™ is NT$65.30, compared to a current price of NT$80.20 — trading 22.8% above its estimated fair value. The current Receivables Turnover is 2.52 and 53.2% below the Medical Diagnostics & Research industry median of 5.39. PuriBlood Medical Co's overall GF Score™ is 72/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For PuriBlood Medical Co (ROCO:6847), the current Receivables Turnover is 2.52 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PuriBlood Medical Co (ROCO:6847) Overvalued in 2026?
Based on GuruFocus' analysis, PuriBlood Medical Co stock appears to be overvalued.
The current stock price of NT$80.20 is trading 22.8% above its estimated GF Value™ of NT$65.30.
GuruFocus considers PuriBlood Medical Co to be Modestly Overvalued.
Key valuation signals for ROCO:6847:
Receivables Turnover: 2.52
GF Value™: NT$65.30 vs. price of NT$80.20 (22.8% above fair value)
Industry Position: 53.2% below the Medical Diagnostics & Research median (#112 of 202)
No single metric tells the full story. See the ROCO:6847 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PuriBlood Medical Co Ltd is engaged in developing solutions for leukoreduction, cell separation, and anti-fouling materials. Its technology protects to supports living beings from medical devices to daily protection. The products of the company include Leukoreduction, Cell Separation, and P-tex.
72GF Score
Get the complete analysis for ROCO:6847
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6847 has been successfully added to your 
